Rosén T, Bengtsson B A
Department of Internal Medicine II, Sahlgrenska Hospital, Göteborg, Sweden.
Lancet. 1990 Aug 4;336(8710):285-8. doi: 10.1016/0140-6736(90)91812-o.
333 consecutive patients with hypopituitarism diagnosed between 1956 and 1987 were retrospectively examined. The patients had been given routine replacement therapy. The overall mortality was higher than in an age and sex matched population. Deaths from vascular disorders were also significantly increased (60 [40 male, 20 female] versus 30.8 expected [23.5, 7.4 female]). The hazard function for vascular death was independent of age at diagnosis, time after diagnosis, calendar year of diagnosis, gender, degree of pituitary insufficiency, hypertension, and diabetes mellitus. Mortality risk was raised irrespective of whether hypopituitarism was due to pituitary adenoma or secondary to other diseases. 7 patients (3 male, 4 female) died from malignant diseases (expected 10.1 and 4.1, respectively). These observations indicate that life expectancy is shortened in patients with hypopituitarism. Growth-hormone deficiency could be a factor in this increased mortality from cardiovascular disease.
对1956年至1987年间确诊的333例垂体功能减退患者进行了回顾性研究。这些患者接受了常规替代治疗。总体死亡率高于年龄和性别匹配的人群。血管疾病导致的死亡也显著增加（60例[40例男性，20例女性]，而预期为30.8例[23.5例，7.4例女性]）。血管性死亡的风险函数与诊断时的年龄、诊断后的时间、诊断的日历年、性别、垂体功能不全的程度、高血压和糖尿病无关。无论垂体功能减退是由垂体腺瘤引起还是继发于其他疾病，死亡风险都会升高。7例患者（3例男性，4例女性）死于恶性疾病（预期分别为10.1例和4.1例）。这些观察结果表明，垂体功能减退患者的预期寿命缩短。生长激素缺乏可能是心血管疾病死亡率增加的一个因素。
